MYONEX NEWS

Adalvo and Myonex strengthen existing exclusive clinical trial supply partnership by adding multiple new assets for global markets

Adalvo and Myonex announced today the expansion of their existing agreement, under which Myonex is the exclusive provider of Adalvo products for clinical trial use globally. Both parties have now expanded this partnership to include multiple new assets.

Anil Okay, CEO of Adalvo, commented, “We at Adalvo are pleased to work with Myonex as our long term exclusive partner for distribution of all Adalvo products in global clinical trial markets. Myonex continues to be highly effective in working with pharmaceutical companies, biotechs, CROs and other service providers around the world to accelerate clinical trials.”

James Lovett, CEO of Myonex, commented, “We are honored to be Adalvo’s exclusive partner to help pharmaceutical companies, biotechs, CROs and other service providers with the complex process of adopting generic and biosimilar medicines in clinical trials, providing substantial benefits in terms of reducing clinical trial costs, assuring adequate, timely supply, and ultimately contributing to the efficiency of drug development for patients.”

About Myonex

Myonex is a leading global complete clinical supply and commercial packaging company offering tailored solutions in central and local drug sourcing, packaging, labeling, and ancillary supply to support each trial or project’s specific requirements and complexities. With locations in the US, Germany, UK & France, we partner with pharmaceutical and biotechnology companies, contract research organizations (CROs), and other clinical trial service providers seeking a flexible, comprehensive solution for their supply needs. Learn more at www.myonex.com

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.

With headquarters in Malta, the company has additional offices in more than 19 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.

We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.

The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.